Compare TRT & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRT | PMN |
|---|---|---|
| Founded | 1958 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 34.6M |
| IPO Year | 1995 | 2022 |
| Metric | TRT | PMN |
|---|---|---|
| Price | $4.92 | $20.91 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $42.67 |
| AVG Volume (30 Days) | 53.2K | ★ 190.5K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 110.28 |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $32,462,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $249.50 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.42 | $0.29 |
| 52 Week High | $14.78 | $20.22 |
| Indicator | TRT | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 36.91 | 83.51 |
| Support Level | N/A | $0.43 |
| Resistance Level | $5.79 | N/A |
| Average True Range (ATR) | 0.45 | 1.49 |
| MACD | 0.07 | 0.41 |
| Stochastic Oscillator | 25.49 | 97.21 |
Trio-Tech International operates in the semiconductor industry, providing manufacturing, testing, and distribution services for semiconductor test equipment and electronic components. It has two main segments: Semiconductor Back-end Solutions (SBS) and Industrial Electronics (IE). The SBS segment, which generates the majority of the Company's revenue, focuses on manufacturing equipment for semiconductor back-end processes, offering testing services, and distributing burn-in test related equipment. The IE segment manufactures equipment for other industries and distributes electronic products outside the semiconductor sector. The Company operates in the United States, Singapore, Malaysia, Thailand, and China, serving customers across multiple regions.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.